BACKGROUND: Atrial fibrillation (AF) is frequent in patients with chronic heart failure (CHF).
Experimental and small patient studies have demonstrated that blocking the renin …

Objectives: We assessed the risk of adverse cardiovascular (CV) outcomes associated with
atrial fibrillation (AF) in the Candesartan in Heart failure-Assessment of Reduction in …

BACKGROUND: Atrial fibrillation (AF) in heart failure (HF) is generally considered a
negative prognostic factor. Recent studies indicate that the incidence of AF might be …

BACKGROUND: Several studies have indicated that treatment with angiotensin converting
enzyme (ACE) inhibitors and angiotensin II type 1 receptor blockers (ARBs) may reduce the …

Objectives: This study assessed the relationship between atrial fibrillation (AF) and
outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an …

Objectives: This study was designed to identify all randomized clinical trial data evaluating
angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for the prevention …

Aims Atrial fibrillation (AF) is an important morbidity–mortality risk factor, especially in
patients with heart failure (HF). Beta-blockers reduce morbidity and mortality in HF. The …

Background: Atrial fibrillation is common in heart failure, but data regarding beta‐blockade
in these patients and its ability to prevent new occurrence of atrial fibrillation are scarce …

BACKGROUND: Epidemiologic studies suggest that inhibition of renin-angiotensin system
with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may …

Background: Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of
AF is largely unknown. Objectives: This study investigated outcomes related to type of AF …